BGT226

• UNSPSC Description:

  BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].

• Target Antigen:

  Autophagy; mTOR; PI3K

• Type:

  Reference compound

• Related Pathways:

  Autophagy;PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BGT226.html

• Smiles:

  O=C(N1C2=CC=C(N3CCNCC3)C(C(F)(F)F)=C2)N(C)C4=C1C5=CC(C6=CC=C(OC)N=C6)=CC=C5N=C4

• Molecular Weight:

  534.53

• References & Citations:

  [1]Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23(9):2399-408.|[2]Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17(22):7116-26.Molecules. 2020 Apr 23;25(8):1980.|Arch Pharm (Weinheim). 2024 Sep;357(9):e2400066.|Front Pharmacol. 2020 Nov 11;11:580407.|Harvard Medical School LINCS LIBRARY|Research Square Print. 2023 Mar 9.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  915020-55-2